dc.contributor.author | Ou, Xiuyuan et al. | |
dc.date.accessioned | 2020-12-17T21:41:02Z | |
dc.date.available | 2020-12-17T21:41:02Z | |
dc.date.issued | 2020-03-27 | |
dc.identifier.uri | https://doi.org/10.1038/s41467-020-15562-9 | en_US |
dc.identifier.uri | https://hdl.handle.net/20.500.12663/2422 | |
dc.description.abstract | Since 2002, beta coronaviruses (CoV) have caused three zoonotic outbreaks, SARS-CoV in 2002–2003, MERS-CoV in 2012, and the newly emerged SARS-CoV-2 in late 2019. However, little is currently known about the biology of SARS-CoV-2. Here, using SARS-CoV-2 S protein pseudovirus system, we confirm that human angiotensin converting enzyme 2 (hACE2) is the receptor for SARS-CoV-2, find that SARS-CoV-2 enters 293/hACE2 cells mainly through endocytosis, that PIKfyve, TPC2, and cathepsin L are critical for entry, and that SARS-CoV-2 S protein is less stable than SARS-CoV S. Polyclonal anti-SARS S1 antibodies T62 inhibit entry of SARS-CoV S but not SARS-CoV-2 S pseudovirions. Further studies using recovered SARS and COVID-19 patients’ sera show limited cross-neutralization, suggesting that recovery from one infection might not protect against the other. Our results present potential targets for development of drugs and vaccines for SARS-CoV-2. | en_US |
dc.language | English | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | Coronavirus | en_US |
dc.subject | Coronavirus Infections | en_US |
dc.subject | Infectious Diseases | en_US |
dc.subject | Antibodies | en_US |
dc.subject | SARS-CoV-2 | en_US |
dc.subject | Betacoronavirus | en_US |
dc.subject | Virus Diseases | en_US |
dc.subject | Host Microbial Interactions | en_US |
dc.title | Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV | en_US |
eihealth.country | Others | en_US |
eihealth.category | Virus: natural history, transmission and diagnostics | en_US |
eihealth.category | Candidate therapeutics RD | en_US |
eihealth.type | Published Article | en_US |
eihealth.maincategory | Save Lives / Salvar Vidas | en_US |
dc.relation.ispartofjournal | Nature Communications | en_US |